Patents Assigned to Institute Pasteur
  • Agents for the in vitro diagnosis of malignant cells originating in the digestive tract
    Patent number: 5188967
    Abstract: In vitro diagnosis of malignant cells originating in the digestive tract by placing a biological specimen in contact with a reagent recognizing the gene coding for human villin.
    Type: Grant
    Filed: February 28, 1991
    Date of Patent: February 23, 1993
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale
    Inventors: Daniel Louvard, Brigitte Dudouet, Sylvie Robine, Monique Arpin, Eric Pringault, Alphonse Garcia
  • Adenyl cyclase derivatives and their biological uses
    Patent number: 5183745
    Abstract: The adenyl cyclase derivatives are atoxic derivatives in which one or several amino acids are different from those present in the toxic protein, the antibodies formed against these derivatives recognize, however, the toxic protein. These derivatives can be used as vaccines.
    Type: Grant
    Filed: October 25, 1989
    Date of Patent: February 2, 1993
    Assignee: Institut Pasteur
    Inventors: Antoine Danchin, Philippe Glaser, Evelyne Krin, Octavien Barzu, Daniel Ladant, Agnes Ullmann
  • Plasmid vectors encoding a protein of a picornavirus
    Patent number: 5182211
    Abstract: The invention relates to an active principle of a vaccine, in which the characteristic epitope is incorporated in the capsid of a picornavirus, in particular of poliovirus, used as a vector. This active principle consists of a viable hybrid picornavirus containing an epitope characteristic of a vaccinating protein, and heterologous with respect to the proteins of this picornavirus, in place of one of its own immunogenic epitopes.
    Type: Grant
    Filed: September 20, 1991
    Date of Patent: January 26, 1993
    Assignee: Institut Pasteur
    Inventors: Marc Girard, Czeslaw Wychowski, Annette Martin
  • Antibody detection of antibodies to viral proteins in serum
    Patent number: 5173400
    Abstract: Protein compositions containing the p18 and p25 proteins of the lymphadenopathy virus are used for detecting antibodies in blood serum as indicative of infection by such virus. The proteins can be used in various conventional ways to perform immunoassays for the detection of the antibodies.
    Type: Grant
    Filed: October 22, 1991
    Date of Patent: December 22, 1992
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Jean C. Chermann, Francoise Barre-Sinoussi, Francoise Vezinet-Brun, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie Theresa Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret
  • Viral vector coding glycoprotein of HIV-1
    Patent number: 5169763
    Abstract: A viral vector comprising at least a portion of the genome of the HIV virus, a gene coding gp160 glycoprotein of the envelope of the HIV virus, as well as the elements providing for the expression of the glycoprotein in cells, wherein the gp160 is expressed as a non-cleavable protein.
    Type: Grant
    Filed: September 24, 1991
    Date of Patent: December 8, 1992
    Assignee: Transgene S.A., Institut Pasteur
    Inventors: Marie-Paule Kieny, Guy Rautmann, Jean-Pierre Lecocq, Simon W. Hobson, Marc Girard, Luc Montagnier
  • Membrane protein having proteolytic activity obtainable from plasmodium falciparum blood schizonts and merozoites
    Patent number: 5153129
    Abstract: An immunogenic composition for use as a vaccine against malaria. It comprises an enzymatically active protease with a molecular weight of 76.000 daltons, characterized by its capacity to react with protective antibodies originating from monkeys resistant to human malaria parasites, particularly to Plasmodium falciparum.
    Type: Grant
    Filed: May 25, 1988
    Date of Patent: October 6, 1992
    Assignee: Institut Pasteur
    Inventors: Luiz Pereira Da Silva, Catherine Breton
  • Steroid/thyroid hormone receptor-related gene inappropriately expressed in human hepatocellular carcinoma
    Patent number: 5149781
    Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences.
    Type: Grant
    Filed: June 20, 1988
    Date of Patent: September 22, 1992
    Assignee: Institut Pasteur
    Inventors: Hugues Blaudin de THE, Agnes Marchio, Pierre Tiollais, Anne Dejean
  • Human Immunodeficiency Virus (HIV) associated with Acquired Immunual Deficiency Syndrome (AIDS), a diagnostic method for aids and pre-aids, and a kit therefor
    Patent number: 5135864
    Abstract: Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS. A kit for in vitro assay of LAS or AIDS is provided.
    Type: Grant
    Filed: November 5, 1987
    Date of Patent: August 4, 1992
    Assignees: Institut Pasteur, The United States of America as represented by the Secretary of The Department of Health and Human Services
    Inventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
  • Hybrid cells producing an antigen characteristic of the hepatitis B virus obtained from hepatocytes and established monkey cells, a process for obtaining these hybrid cells and their application to the production of the aforesaid antigen
    Patent number: 5112748
    Abstract: The invention concerns hybrid cells transformed or transformable by a cloned DNA containing the sequence coding for the antigen HBs. They are characterized in that they contain, on the one hand, at least a part of the genetic heritage of monkey hepatocyte cells and, on the other hand, a genetic marker permitting them to grow in a selective medium or one containing an active principle normally lethal to the VERO cells from which the hybrid is derived, but able to be inactivated by the polypeptide expressed by the said genetic marker.
    Type: Grant
    Filed: February 19, 1987
    Date of Patent: May 12, 1992
    Assignee: Institut Pasteur and Centre National de la Recherche Scientifique
    Inventors: Nicole Chenciner, Jean-Francois Houssais
  • Probe containing a modified nucleic acid recognizable by specific antibodies and use of this probe to detect and characterize a homologous dna sequence
    Patent number: 5098825
    Abstract: A method and kit for detecting a predetermined nucleotide sequence in a specimen using a nucleic acid probe modified with N-2-acetylaminofluorene (AAF).
    Type: Grant
    Filed: April 24, 1990
    Date of Patent: March 24, 1992
    Assignee: Institut Pasteur
    Inventors: Paul Tchen, Philip Kourilsky, Marc Leng, Anne B. Cami
  • A43 kDa antigenic protein of Bordetella recognized by polyclonal antibodies to adenylate cyclase but devoid of calmodulin-activatable adenylate cyclase activity
    Patent number: 5095094
    Abstract: The proteins of the invention are specifically recognized by polyclonal anti-AC antibodies raised against purified AC preparations, devoid of adenylate cyclase CaM-activable activity and devoid of affinity for CaM.
    Type: Grant
    Filed: February 20, 1990
    Date of Patent: March 10, 1992
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
    Inventors: Colette Brezin, Hoang-Oanh Nghiem, Jean Luc Boucaud, Jean M. Alonso
  • Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (HIV-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits
    Patent number: 5079342
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Grant
    Filed: February 11, 1987
    Date of Patent: January 7, 1992
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Geutard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Transhybridomas
    Patent number: 5073490
    Abstract: Tissue cell culture preparations derived from the cells of a transgenic animal are disclosed. These tissue cell preparations are capable of expressing a non-analogous gene product, i.e., a gene product which is not naturally produced by the animal cells.Transhybridomas, i.e., hybridomas and immortalized cells created using cells obtained from transgenic animals, and methods for creating these transhybridomas are also disclosed. In particular, two transhybridomas, A 15.9 and B 6.4, both capable of producing human growth hormone, have been disclosed.
    Type: Grant
    Filed: February 27, 1990
    Date of Patent: December 17, 1991
    Assignee: Institut Pasteur
    Inventors: Charles Babinet, Dominique Morello
  • Novel lymphokine for suppressing platelet activation
    Patent number: 5071959
    Abstract: New lymphokine and its isolation and purification process. Said lymphokine is comprised of a factor obtained from T cells stimulated by concanavaline A or by an antigen capable of inhibiting the IgE-dependent platelet citotoxicity with respect to young larvae of S. Mansoni, of strongly reducing the chemiluminescence of blood platelets in a reaction IgE-anti-IgE, which is a correlate of the anti-parasite cytotoxicity, and of inhibiting the platelet activation in non-IgE dependent intolerences. Application as suppressor agent for suppressing platelet activation and as immunomodulator medicament of allergies.
    Type: Grant
    Filed: March 1, 1988
    Date of Patent: December 10, 1991
    Assignees: Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale - INSERM
    Inventors: Andre Capron, Michel Joseph, Veronique Pancre, Claude Auriault
  • Process and reagents for the detection of a monocaternary nucleic acid, particularly a RNA in a biological material and particularly in leucocyte preparations
    Patent number: 5070009
    Abstract: The invention relates to a process for the in vitro detection of a determined RNA, particularly of a mRNA connected with a genetic abnormality in a biological material. This process comprises a treatment of the cells contained in that material for the sake of releasing their cellular components and of exposing the RNAs yet without denaturing other nucleic acids, and then the detection operation comprising contacting RNA sought to be detected, in presence of the other cellular components, with a nucleotidic sequence complementary of the RNA sought.
    Type: Grant
    Filed: September 15, 1988
    Date of Patent: December 3, 1991
    Assignee: Institut Pasteur
    Inventor: Michel Crepin
  • Retrovirus capable of causing AIDS, means and method for detecting it in vitro
    Patent number: 5066782
    Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399.It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis.It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hydridization probes, derived from the RNA of HIV-2.
    Type: Grant
    Filed: January 10, 1990
    Date of Patent: November 19, 1991
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, Francois Clavel, Mireille Guyader, Pierre Sonigo, Francoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
  • Peptides comprising an immunogenic site of poliovirus and DNAs containing nucleotide sequences coding for these peptides
    Patent number: 5061623
    Abstract: The invention relates to a DNA fragment containing at the most 315 pairs of nucleotides coding for a peptide which can be recognized by antibodies acting both against the "C" and "D" particles of the same poliovirus and against the VP-1 structural polypeptide of the capsid of this poliovirus. This peptide contains in particular the following sequence: Asp Asn Pro Ala Ser Thr Asn Lys Asp Lys Leu.
    Type: Grant
    Filed: June 15, 1990
    Date of Patent: October 29, 1991
    Assignee: Institut Pasteur
    Inventors: Marc Girard, Sylvie Van Der Werf
  • Method and kit or detecting antibodies to antigens of Human Immunodeficiency Virus type 2 (HIV-2)
    Patent number: 5055391
    Abstract: The invention relates to a new variety of retroviruses designated Human Immunodeficiency Virus Type II, HIV-II, samples of which have been deposited at CNCM as I-502 and I-532. It also concerns purified forms of the antigens which can be obtained from this virus, in particular from the gp 36 and gp 130-140 proteins. These various antigens are useful in medical diagnosis and kits, in particular by being placed in contact with serum of the patient to be diagnosed. Lastly, the invention relates to immunizing compositions, in particular containing at least one of glycoproteins gp 36 and gp 130-140.
    Type: Grant
    Filed: January 3, 1990
    Date of Patent: October 8, 1991
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Denise Guetard, Francoise Brun-Vezinet, Francois Clavel
  • Peptides related to human immunodeficiency virus II (HIV-2)
    Patent number: 5051496
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Grant
    Filed: January 16, 1987
    Date of Patent: September 24, 1991
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Variant of LAV viruses
    Patent number: 5034511
    Abstract: A variant of a LAV virus, designated LAV.sub.ELI and capable of causing AIDS. The cDNA and antigens of the LAV.sub.ELI virus can be used for the diagnosis of AIDS and pre-AIDS.
    Type: Grant
    Filed: April 13, 1987
    Date of Patent: July 23, 1991
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier